CSPC Pharmaceutical Group (1093) Price & Analysis

Compare

16 Followers

1093 Stock Chart & Stats

Day’s Range― - ―

52-Week RangeHK$4.27 - HK$10.74

Previous CloseN/A

Volume61.16M

Average Volume (3M)170.50M

Market Cap

$115.03B

Enterprise ValueHK$49.10B

Total Cash (Recent Filing)$8.25B

Total Debt (Recent Filing)$507.33M

Price to Earnings (P/E)25.0

Beta0.95

Next Earnings

Aug 20, 2025

EPS Estimate

0.15

Last Dividend Ex-Date

Jun 04, 2025

Dividend Yield2.69%

Share Statistics

EPS (TTM)0.14

Shares Outstanding11,521,952,000

10 Day Avg. Volume231,206,450

30 Day Avg. Volume170,503,131

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.43

Enterprise Value/Revenue1.59

Enterprise Value/Gross Profit2.27

Enterprise Value/Ebitda7.34

Forecast

1Y Price Target

$7.77

Price Target Upside-19.72% Downside

Rating ConsensusModerate Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Earnings GrowthCSPC's BD deals are anticipated to be a key sustainable driver of earnings growth, contributing positively to revenue and net profit projections.

Out-licensing DealsCSPC Pharmaceutical is expected to engage in three large-scale out-licensing deals, each potentially exceeding US$5bn in value, which could significantly boost revenue.

Bears Say

Profit DeclineCSPC released profit warning for FY24, with management expecting net profit to decline by 26% due to weak finished drug sales.

Revenue PressureSales of finished drugs declined, driven by a decrease in CNS products due to channel compensation following NRDL price cuts.

CSPC Pharmaceutical Group News

CSPC Pharmaceutical’s Semaglutide Injection Gains NMPA Approval for Diabetes Treatment

An update from CSPC Pharmaceutical Group ( ($HK:1093) ) is now available. CSPC Pharmaceutical Group announced that its...

3d ago

CSPC Pharmaceutical Partners with Madrigal for Global Expansion of Diabetes Drug

An update from CSPC Pharmaceutical Group ( ($HK:1093) ) is now available. CSPC Pharmaceutical Group has entered into...

9d ago

CSPC Pharmaceutical’s Mesalazine Tablets Gain Approval in China

CSPC Pharmaceutical Group ( ($HK:1093) ) has shared an announcement. CSPC Pharmaceutical Group Limited has announced that its...

1M ago

EO-3021 Study Termination: Implications for Elevation Oncology and Partners

Eli Lilly And Company (($LLY)), GlaxoSmithKline (($GSK)), GlaxoSmithKline plc (UK) (($GB:GSK)), CSPC Pharmaceutical Group (($CHJTF)), Elevation Oncology, Inc....

1M ago

GSK

LLY

CSPC Pharmaceutical Gains Approval for MMA Treatment Trials in China

CSPC Pharmaceutical Group ( ($HK:1093) ) has provided an update. CSPC Pharmaceutical Group has received approval from China’s...

1M ago

CSPC Pharmaceutical Group Enhances Nomination Committee with New Appointment

An announcement from CSPC Pharmaceutical Group ( ($HK:1093) ) is now available. CSPC Pharmaceutical Group Limited has announced...

1M ago

CSPC Pharmaceutical Group Announces Board Composition

The latest announcement is out from CSPC Pharmaceutical Group ( ($HK:1093) ). CSPC Pharmaceutical Group Limited has announced...

1M ago

CSPC Pharmaceutical Group Updates Nomination Committee Terms

CSPC Pharmaceutical Group ( ($HK:1093) ) has issued an announcement. CSPC Pharmaceutical Group Limited has updated the terms...

1M ago

CSPC Pharmaceutical Group Renews Lease Agreements Amid Regulatory Compliance

CSPC Pharmaceutical Group ( ($HK:1093) ) has shared an announcement. CSPC Pharmaceutical Group Limited has announced the signing...

2M ago

CSPC Pharmaceutical’s Meloxicam Injection Approved in China

The latest update is out from CSPC Pharmaceutical Group ( ($HK:1093) ). CSPC Pharmaceutical Group has announced that...

2M ago

1093 FAQ

What was CSPC Pharmaceutical Group Limited’s price range in the past 12 months?

CSPC Pharmaceutical Group Limited lowest stock price was HK$4.27 and its highest was HK$10.74 in the past 12 months.

What is CSPC Pharmaceutical Group Limited’s market cap?

CSPC Pharmaceutical Group Limited’s market cap is $115.03B.

When is CSPC Pharmaceutical Group Limited’s upcoming earnings report date?

CSPC Pharmaceutical Group Limited’s upcoming earnings report date is Aug 20, 2025 which is in 12 days.

How were CSPC Pharmaceutical Group Limited’s earnings last quarter?

CSPC Pharmaceutical Group Limited released its earnings results on May 29, 2025. The company reported HK$0.141 earnings per share for the quarter, beating the consensus estimate of HK$0.131 by HK$0.01.

Is CSPC Pharmaceutical Group Limited overvalued?

According to Wall Street analysts CSPC Pharmaceutical Group Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does CSPC Pharmaceutical Group Limited pay dividends?

CSPC Pharmaceutical Group Limited pays a Semiannually dividend of HK$0.1 which represents an annual dividend yield of 2.69%. See more information on CSPC Pharmaceutical Group Limited dividends here

What is CSPC Pharmaceutical Group Limited’s EPS estimate?

CSPC Pharmaceutical Group Limited’s EPS estimate is 0.15.

How many shares outstanding does CSPC Pharmaceutical Group Limited have?

CSPC Pharmaceutical Group Limited has 11,521,952,000 shares outstanding.

What happened to CSPC Pharmaceutical Group Limited’s price movement after its last earnings report?

CSPC Pharmaceutical Group Limited reported an EPS of HK$0.141 in its last earnings report, beating expectations of HK$0.131. Following the earnings report the stock price went up 11.735%.

Which hedge fund is a major shareholder of CSPC Pharmaceutical Group Limited?

Currently, no hedge funds are holding shares in HK:1093

CSPC Pharmaceutical Group Stock Smart Score

Outperform

Fundamentals

Return on Equity

13.20%

Trailing 12-Months

Asset Growth

-6.81%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

CSPC Pharmaceutical Group Limited

CSPC Pharmaceutical Group (1093) is a leading pharmaceutical company based in China, engaged in the development, manufacture, and sale of pharmaceutical products. The company operates across several key sectors, including innovative drug development, generic drugs, and bulk drugs. CSPC focuses on various therapeutic areas such as oncology, cardiovascular, and central nervous system disorders, offering a diverse portfolio of products that cater to both domestic and international markets.

CSPC Pharmaceutical Group (1093) Earnings & Revenues

Historic Earnings Reports

1093 Stock 12 Month Forecast

Average Price Target

HK$7.77

▼(-19.72% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"HK$3","5":"HK$5","7":"HK$7","9":"HK$9","11":"HK$11"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10.089287207835696,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$10.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.7707396305,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$7.77</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.999646782872,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,5,7,9,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.7,7.883791323679669,8.067582647359337,8.251373971039007,8.435165294718676,8.618956618398345,8.802747942078014,8.986539265757683,9.170330589437352,9.35412191311702,9.537913236796689,9.721704560476358,9.905495884156027,{"y":10.089287207835696,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.7,7.705441510038462,7.710883020076923,7.716324530115385,7.721766040153846,7.727207550192308,7.732649060230769,7.738090570269231,7.743532080307692,7.748973590346154,7.754415100384615,7.759856610423077,7.765298120461538,{"y":7.7707396305,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.7,7.492280521759385,7.284561043518769,7.076841565278154,6.869122087037539,6.661402608796923,6.453683130556308,6.245963652315693,6.038244174075077,5.830524695834462,5.6228052175938465,5.415085739353231,5.2073662611126155,{"y":4.999646782872,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.743,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.101,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.008,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.546,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.815,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.202,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.718,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.422,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.649,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.41,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.051,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.611,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >